Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

WHO Backs Pfizer’s Paxlovid For High-Risk COVID-19 Patients

But Access Obstacles Remain In Lower-Income Countries

Executive Summary

An international group of experts has issued new guidance on the use of therapeutics in patients with non-severe COVID-19.

You may also be interested in...



Global COVID-19 Access Program Facing ‘Financial Crisis’

ACT-A, an initiative led by the World Health Organization and involving international health agencies, has significantly improved access to COVID-19 medical countermeasures in lower-income countries. However, further progress could be hindered by a funding shortfall, and ACT-A has urged donors to contribute their fair share.

New Zealand Hikes Fees To Reflect Changes In Drug Applications

Following a consultation last year, Medsafe has set new fee levels that take account of both cost-recovery principles and a 4.2% increase in the consumer price index. 

Bavarian Nordic To Supply Vaccine As Monkeypox Appears In UK & Portugal

The monkeypox cases reported this month are evidence of chains of transmission of the virus, according to the European Centre for Disease Prevention and Control, which says that vaccination of high-risk close contacts should be considered after a benefit-risk assessment.

Topics

Related Companies

UsernamePublicRestriction

Register

PS146058

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel